References
- Praxbind(R) [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc.; October 2015 [cited 2016 Oct 7]. Available from: http://docs.boehringer-ingelheim.com/Prescribing%20Infor-mation/PIs/Praxbind/Praxbind.pdf
- Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373:511–520.
- Gosselin RC, Dwyre DM, Dager WE. Measuring dabigatran concentrations using a chromogenic ecarin clotting time assay. Ann Pharmacother. 2013;47:1635–1640.
- Yogaratnam D, Ditch K, Medeiros K, et al. Idarucizumab for reversal of dabigatran-associated anticoagulation. Ann Pharmacother. 2016;50:847–854.
- Marino KK, Santiago RA, Dew RB, 3rd, et al. Management of dabigatran-associated bleeding with two doses of idarucizumab plus hemodialysis. Pharmacotherapy. 2016;36:e160–e165.
- Rottenstreich A, Jahshan N, Avraham L, et al. Idarucizumab for dabigatran reversal – does one dose fit all? Thromb Res. 2016;146:103–104.
- Dager WE, Gosselin RC, Kitchen S, et al. Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: a multicenter, in vitro study. Ann Pharmacother. 2012;46:1627–1636.
- Van Blerk M, Bailleul E, Chatelain B, et al. Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey. Thromb Haemost. 2015;113:154–164.
- Lindahl TL, Baghaei F, Blixter IF, et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost. 2011;105:371–378.
- Dager WE, Banares L. Reversing the anticoagulation effects of dabigatran. Hosp Pract (1995). 2017;45:29–38.